Although the results were not statistically significant for complete remission at shorter follow-up intervals (6 and 12 months), there was an observed trend towards improved outcomes in patients treated with rituximab.
← all excerpts
Efficacy and safety of rituximab for membranous nephropathy in adults: a meta-analysis of RCT.
1
—
—